Abstract: The present invention relates to the use of at least one polyene macrolide for the preparation of pharmaceutical compositions for the treatment of diseases that are associated with an impaired energy turnover. Particularly, the present inventions allows to specifically stimulate the energy conversion in human cell, i.e. to stimulate the cell metabolism, and thus to treat or prevent a series of diseases.

Abstract: The method of this invention is directed to a treatment of depression in men and women and to a treatment of pre-menstrual syndrome (PMS) in women by administering to a patient a therapeutically effective amount of chromium in a pharmaceutically acceptable form either alone or in conjunction with the administration of a standard antidepressant composition, such as a selective serotonin reuptake inhibitor composition. Chromium, preferably in the form of chromium picolinate, is administered to the patient at dosages in a preferred range of about 200 to about 500 micrograms chromium.

Abstract: Hot flashes (intense heat sensation, flushing, profuse sweating, palpitations, and/or sense of anxiety) in a menopausal woman may be substantially eliminated or ameliorated by administering to a woman in need of treatment an effective amount of ingestible material which has as substantially the only active ingredient a herbal complex. These exemplary herbal complex formula utilize a number of different species of herbs using the unique properties found in different parts of the plant, the root, the leaves, the aerial parts, the bark and the rhizomes.

Abstract: The present invention relates to a method of administering progesterone to a normogonadal or a functionally agonadal human female undergoing an assisted reproduction technique. The invention further provides a method of hormone replacement for a human female. In a preferred embodiment of the present invention, progesterone is provided by intravaginal administration of a progesterone-containing polysiloxane ring.

Abstract: A method of treating animals, particularly rhea and ostrich chicks with adipose depletion, by injection with an oil derived from rhea or ostrich adipose or by injection with an active component of the oil that increases anti-inflammatory capabilities and phospholipid formation.

Abstract: A pharmaceutical composition for and methods of treatment of menstrual disorders, e.g., dysmenorrhea, in a non-pregnant female, preterm labor, preeclampsia and/or fetal growth retardation in a pregnant female mammal, treatment of atherosclerotic vascular disease and hypertension in males as well as females, and for hormone replacement therapy in peri- and post-menopausal females, comprising administering effective amounts of an endothelin antagonist and/or an endothelin synthase inhibitor or both, in combination witha progestin, and/or an estrogen, and/ora cyclooxygenase inhibitor, and/ora nitric oxide donor and/or nitric oxide substrate,to prevent and/or ameliorate said conditions, are disclosed. In the method aspects, the endothelin antagonist and/or endothelin synthase inhibitor can be administered alone for treatment of menstrual disorders, e.g., dysmenorrhea, in a non-pregnant female, preterm labor, preeclampsia and/or fetal growth retardation in a pregnant female mammal.

Abstract: A compressed medicinal tablet comprising a tablet core and a sugar coating, said sugar coating containing a dose of a hormonal steroid and a steroid release rate controlling amount of microcrystalline cellulose.

Abstract: A method of managing or alleviating carbohydrate craving, binge eating, anxiety, or depression entails administering an aqueous carbohydrate blend containing dextrose, dextrin, maltodextrin or a mixture thereof, and starch, pregelatinized starch, or a mixture thereof. The aquous mixture is essentially free of protein, has a pH of less than 6 and has a ratio of water to carbohydrate blend of about 3-12 mL water to 1 g of carbohydrate blend.

Abstract: A sugar coating composition for application to a compressed medicinal tablet comprising a sugar, a dose of a hormonal steroid and a steroid release rate controlling amount of microcrystalline cellulose.

Abstract: Compositions of finely divided powder of safflower seed or its extract, and methods for the treatment of rheumatoid-based arthritic diseases and menopause.

Abstract: Antigestagens inhibit prostaglandin synthesis by the uterus and thus can be used to treat symptoms of dysmennhorea.

Abstract: The present invention is directed to an herbal compound which aids in the relief of symptoms caused by female hormonal imbalances. The herbal compound of the present invention preferably comprises red raspberry, bayberry, blue cohosh, capsicum, cascara sagrada, damiana, ginger, valerian and a binding agent. The ratio of red raspberry to the other herbal constituents is preferably two to one. The herbal compound preferably further comprises a binding agent which comprises cellulose, to hold the herbal components together, as well as vegetable powder, used as a food carrier so that the herbal compound can be safely and effectively taken on an empty stomach. The binding agent preferably also comprises ingredients to allow the herbal compound to dissolve in the stomach. In the preferred embodiment, the herbal compound and binding agents are formed as a tablet, with the exterior surface thereof coated with a food glaze.

Abstract: The present invention relates to a transdermal therapeutic formulation comprising capsaicin, a nonsteroidal anti-inflammatant and pamabrom. The formulation is used to alleviate pain or discomfort in a mammal by being applied to the skin of the mammal thereby causing the active ingredients in the formulation to pass into and/or through the skin of the mammal. In a preferred embodiment of the present invention, the formulation is used in patch form for the treatment of the pain and discomfort associated with menstrual cramps, water retention (e.g., "bloating") and/or muscular pain (e.g., muscular back pain).

Abstract: A composition for the treatment of premenstrual syndrome comprising an effective amount of calcium, magnesium, an analgesic and a diuretic sufficient to reduce the symptoms of premenstrual syndrome.

Abstract: A composition is disclosed for alleviating or managing symptoms associated with premenstrual syndrome "PMS" comprising an effective amount of an aqueous mixture of water and a rapidly digestible carbohydrate blend. The aqueous mixture is essentially free of protein and is characterized by a certain pH and ratio of water to carbohydrate blend. Methods of use of the composition for alleviating or managing symptoms associated with PMS are also disclosed.

Abstract: A method is provided for treating dysmenorrhea (menstrual cramps) employing an interphenylene 7-oxabicycloheptyl substituted heterocyclic amide prostaglandin analog thromboxane A.sub.2 receptor antagonist such as ifetroban, alone or in combination with a non-steroidal anti-inflammatory drug (NSAID).

Abstract: This invention relates to a composition for use in the treatment or prevention of iodine deficiency diseases or disorders such as fibrocystic dysplasia of the breast, breast cancer, endometriosis, ovarian cysts and premenstrual syndrome. More particularly, this invention relates to a composition for the treatment or prevention of iodine deficiency diseases or disorders, the composition comprising elemental iodine (I.sub.2) which may also be referred to as metallic iodine or iodine metal. The elemental iodine can be used with any pharmaceutically acceptable carrier.

Abstract: The present invention is directed to cyclophasic hormonal regimens which comprise antiprogestin and progestin for human contraception whereby progestin is administered in the alternating presence and absence of an antiprogestin in effective amounts to upregulate steroid receptor levels or is alternatively dosed with effective amounts of antiprogestin to upregulate steroid receptor levels. The present invention also provides an estrogen containing cyclophasic hormonal regimen for climacteric or menopausal hormone replacement therapy comprising the administration of an effective hormone replacement amount of estrogen in alternating doses with a combined amount of estrogen and an effective amount of antiprogestin to inhibit proliferation of endometrial tissue caused by the administration of the estrogen.

Abstract: A pharmaceutical composition having a form suitable for transmucosal administration containing progesterone and/or 17-.beta.-estradiol as an active ingredient.

Abstract: This invention provides a method for treating hypothalamic amenorrhea in a non-depressed female mammal by administering to the mammal an effective amount of a hydroxycycloalkanephenethyl amine compound of the following structural formula: ##STR1## in which A is a moiety of the formula ##STR2## wherein the dotted line represents optional unsaturation;R.sub.1 is hydrogen or alkyl;R.sub.2 is alkyl;R.sub.4 is hydrogen, alkyl, formyl, or alkanol;R.sub.5 and R.sub.6 are, independently, hydrogen, hydroxyl, alkyl, alkoxy, alkanoyloxy, cyano, nitro, alkylmercapto, amino, alkylamino, dialkylamino, alkanamido, halo, trifluoromethyl, or taken together, methylene dioxy;R.sub.7 is hydrogen or alkyl; andn is 0, 1, 2, 3, or 4;or a pharmaceutically acceptable salt thereof.

Abstract: A method is provided for preventing or treating symptoms of menopause, premenstrual syndrome, or a condition resulting from reduced levels of endogenous estrogen, by administering to the woman an effective amount of an isoflavonoid. The invention also features a therapeutic dietary product, containing isoflavonoids, for preventing or treating symptoms of conditions resulting from reduced or altered levels of endogenous estrogen.

Abstract: Emu oil is therapeutically used in methods for lowering cholesterol, triglycerides and low density lipoproteins and increasing high density lipoproteins; preventing and treating allergies; preventing scarring; treating headaches; preventing nose bleeds; treating and preventing cold and flu symptoms; and relieving discomfort associated with menstruation. Additionally, emu oil acts as an effective chemical buffer in combination with glycolic acid.

Abstract: A liquid composition for the relief of discomfort, in particular, premenstrual and menstrual discomfort including, as active pharmaceutical agents, an effective amount of one or more of an analgesic, an antihistamine and a diuretic, the active agents being dissolved in a liquid vehicle, the composition containing 5-25 percent by volume alcohol and being flavored with an active flavoring composition including (1) citrus and mint ingredients, (2) vanilla and mint ingredients, or (3) citrus, vanilla and mint ingredients, the active flavoring ingredients being present in an amount sufficient to mask the unpleasant taste of the pharmaceutically active agents.

Abstract: The present invention provides novel methods of inhibiting uterine fibroid disease and endometriosis in women comprising administering to a woman in need of treatment an effective amount of a compound of formula I ##STR1## wherein R.sup.1 and R.sup.2 may be the same or different provided that, when R.sup.1 and R.sup.2 are the same, each is a methyl or ethyl group, and, when R.sup.1 and R.sup.2 are different, one of them is a methyl or ethyl group and the other is a benzyl group, or a pharmaceutically acceptable salt thereof.

Abstract: A method of treating a pathological condition of an internal organ in a patient which comprises topically applying capsaicin to the skin of the patient containing nerves which lead to the spinal cord segments corresponding to the internal organ without the need of systemic absorption of the capsaicin.

Abstract: A method of detecting and treating malignant and non-malignant tissue abnormalities and lesions of the skin; conjunctiva; respiratory, digestive and vaginal mucosa; endometrium and urothelium; and for ablating the endometrial tissue and treating body fluids, including blood containing suspended abnormal cells, and for treating cancers of the nervous system in which 5-aminolevulinic acid or precursor thereof is administered to the patient in an amount sufficient to induce synthesis fluorescence and/or photosensitizing concentrations of a protoporphyrin IX in the abnormal cells, followed by exposure of the abnormal cells to light of photoactivating wavelengths.

Abstract: This invention relates to a composition for use in the treatment of iodine deficiency diseases such as fibrocystic dysplasia of the breast, breast cancer, endometriosis and premenstrual syndrome. The composition may also be used for the prophylaxis of breast cancer. More particularly, this invention relates to a composition for She treatment of iodine deficiency diseases, the composition comprising a solution of elemental iodine (I.sub.2) which may also be referred to as metallic iodine or iodine metal. The elemental iodine is soluble in water which leaves it thermodynamically free. The term "aqueous iodine" may also be used to refer to such an aqueous solution.

Abstract: A method of detecting and treating malignant and non-malignant tissue abnormalities and lesions of the skin; conjunctiva; respiratory, digestive and vaginal mucosa; endometrium and urothelium; and for ablating the endometrial tissue and treating body fluids containing suspended abnormal cells, and for treating cancers of the nervous system in which 5-aminolevulinic acid or precursor thereof is administered to the patient in an amount sufficient to induce synthesis fluorescence and/or photosensitizing concentrations of of protoporphyrin IX in the abnormal cells, followed by exposure of the abnormal cells to light of photoactivating wavelengths.

Abstract: Compounds of the general formula ##STR1## and the pharmaceutically acceptable salts thereof whereinn is an integer of from 0 to 6;Y is CH.sub.2, O, SO.sub.2, --CONH--, --NHCO--, or ##STR2## R.sup.1 and R.sup.2 are independently hydrogen,C.sub.1-8 alkyl,heterocyclyl C.sub.0-4 alkyl,aryl C.sub.0-4 alkyl,amino C.sub.1-4 alkyl,C.sub.1-4 alkylamino C.sub.1-4 alkyl, orC.sub.3-8 cycloalkylwherein R.sup.1 and R.sup.2 may be unsubstituted or substituted with one or more groups chosen from R.sup.3, whereR.sup.3 ishydrogen,C.sub.1-6 alkyl,hydroxy C.sub.0-4 alkyl,carboxy C.sub.0-4 alkyl,C.sub.1-4 alkyloxy C.sub.0-4 alkyl,heterocyclyl C.sub.0-4 alkyl,aryl C.sub.0-4 alkyl,halogen, orCF.sub.3 ;R.sup.4 isC.sub.1-6 alkyl,heterocyclyl C.sub.0-4 alkyl, oraryl C.sub.0-4 alkyl;R.sup.5 ishydrogen,C.sub.1-6 alkyl,aryl C.sub.0-3 alkyl, orC.sub.1-6 alkylcarbonyloxymethylare used in a method of treating osteoporosis by inhibiting the bone resorption activity of osteoclasts.

Abstract: Continuous administration of compositions containing a fixed quantity of synthetic estrogen in combination with a synthetic progestogenic agent are useful to relieve menopausal symptoms, to prevent osteoporosis and for other hormone-replacement treatments. Also described is an improved manufacturing process for such compositions especially for low tablet dosage forms.

Abstract: This invention is directed to a delivery system and a method useful for the treatment of benign ovarian secretory disorders in female mammals by administering an LHRH composition. The method comprises administering during the entire follicular phase of the menstrual cycle, beginning at the time of menses, an LHRH composition and sufficient levels of an estrogenic steriod to counteract the possibility of side effects which may develop during prolonged therapy with LHRH. Following the follicular phase, at the beginning of the luteal phase, and for the entire course of the luteal phase, the LHRH/estrogenic steroid combination administered during the follicular phase, in combination with a physiological amount of progestational steroid, is administered.

Abstract: Substituted indoles and derivatives thereof are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as central nervous system agents and are particularly useful as dopaminergic, antipsychotic, and antihypertensive agents as well as for treating hyperprolactinaemia-related conditions and central nervous system disorders.

Abstract: This invention is concerned with a contraceptive formulation and a method of contraception which employs a combination of estrogen and progestin and wherein a short period of relatively dominant estrogenic activity alternates with a short period of relatively dominant progestagenic activity. The invention also concerns a hormonal replacement formulation and method for use in menopausal or castrate women which employs a similar combination of estrogen and progestin.

Abstract: Tartar formation on teeth is prevented with compositions of a sodium salt ethylenediaminetetraacetic acid having a pH between about 5.5 and 9.0 in a carrier which permits application to the teeth. Aqueous solution may be used for this purpose as well as toothpaste compositions.

Abstract: A liquid composition for the relief of premenstrual and menstrual discomfort comprising, as active pharmaceutical agents, an effective amount of an analgesic, an antihistamine, and a diuretic, said active agents being dissolved in a liquid vehicle, said composition containing 5-25 percent by volume alcohol and being flavored with active flavoring elements selected from the group consisting of citrus, vanilla, and mint, said active flavoring ingredients being present in an amount sufficient to mask the unpleasant taste of the pharmaceutically active agents.

Abstract: New N-(2-cycloalkylamino)ethyl-substituted benzamides having a powerful stimulating activity on gastric motility and with a low central anti-dopaminergic activity are described. The synthesis and the pharmaceutical preparation for therapeutical use are also described.

Abstract: A method for the treatment of premenstrual syndrome (PMS) by administering a therapeutically effective dose of calcium to an individual manifesting symptoms of PSM. Calcium may be administered in any appropriate form and manner. In a randomized, double-blind crossover placebo-controlled study of 33 women PMS symptomology was reduced on calcium treatment during both the luteal and the menstrual phases.

Abstract: Formulae, means, and methods for the sublingual ingestion of natural Progesterone comprising milling and blending natural Progesterone such that it can be absorbed by the sublingual mucosae of a patient and applying it to said sublingual mucosae in a form which permits such absorption.

Abstract: A pharmaceutical composition is provided for oral administration. The composition comprises estradiol dissolved in an oil vehicle containing a suspension of micronized progesterone. The oil vehicle is high in glycerides of polyunsaturated fatty acids. The estradiol and micronized progesterone contained in the oil are more readily absorbable in the blood stream and achieve enhanced estradiol and progesterone blood serum levels. The pharmaceutical composition according to the invention can be readily formulated into capsules and administered for the treatment of menopausal symptoms.

Abstract: Disclosed is a method for treating menopausal symptoms and treating and preventing osteoporosis, wherein a true antiestrogen is administered and estrogen is not. This treatment is effective for female osteoporosis and can also be used to treat male osteoporosis. Examples of true antiestrogens are clomiphene, and its isomers, citrates and derivatives, as well as several other compounds which appear in the specification.

Abstract: The invention relates to the use of clomiphene and its citrate salt in predicting fertility in a human female.

Abstract: A method for producing, in a functionally agonadal human female body, an environment suitable for the implantation, nutrition, and development of an embryo, comprising the placement of at least one carrier containing at least one releasable steroid hormone into the vagina of the human female.

Abstract: Antibody or antigen containing microparticles for the active or passive immunization of the internal female reproductive organs, comprising: microparticles of an antigen or antibody incorporated in a matrix material which is biocompatible and biologically degradable, said microparticles capable of being transported after deposition in the vagina by the natural transport mechanism of the internal female reproductive organs across the cervix into the uterus.

Abstract: The invention involves a method for treating symptoms secondary to estrogen deficiency without using estrogen. Weakly estrogenic antiestrogens are administered to estrogen deficient women in the absence of estrogen administration. Maximum estrogenic activity is therby obtained and the harmful side effects of estrogen therapy are avoided.

Abstract: A product for treatment of arthritis and migraine is formed from the Feverfew plant. The leaves and part of the stalk are harvested from the Chrysanthemum parthenium form of the plant immediately prior to flowering and then freeze dried, milled and converted into capsule or tablet form for human use.

Abstract: Plant extracts are employed to provide a menses inducing composition for topical application. Common commercially available fenugreek seeds and commercially available ginger are mixed in a preferred range of ratios and combined in a dry powder form for topical application to the outside of the abdomen of the female to induce menses.

Abstract: A method of decreasing the concentration of prolactin in an animal, which comprises administering to the animal a prolactin-decreasing amount of cysteamine.

Abstract: Antibody or antigen containing microparticles for the active or passive immunization of the internal female reproductive organs, comprising: microparticles of an antigen or antibody incorporated in a matrix material which is biocompatible and biologically degradable, said microparticles capable of being transported after deposition in the vagina by the natural transport mechanism of the internal female reproductive organs across the cervix into the uterus.

Abstract: An agent and method for treating vasomotor disorders, particularly migraine and menstrual pain is provided wherein the method comprises administering to said patient, intravenously or orally, an effective dose of the agent according to the invention, Vitamin B.sub.6. The effective dose of vitamin B.sub.6 is at least about 100 mg., preferably at least about 300 mg. and most preferably at least about 400 mg. Vitamin B.sub.2 may also be administered for particularly effective results.

Abstract: Tetracyclines, antibacterial and non-antibacterial tetracyclines, have been found to be useful in the treatment of osteoporosis in humans by administering to the human suffering from osteoporosis an effective amount of a tetracycline to enhance bone protein synthesis. Tetracyclines which have been found to be effective in the treatment of osteoporosis in humans include minocycline, doxycycline and dedimethylaminotetracyline.